Johnson & Johnson touts Phase 3 win for TALVEY combination in relapsed multiple myeloma

Johnson & Johnson said it has reported Phase 3 results for a combination regimen aimed at treating relapsed or refractory multiple myeloma, a cancer of plasma cells that typically becomes harder to control after initial therapy. The company highlighted the MonumenTAL-3 study, reporting improved outcomes for patients treated with TALVEY in combination with DARZALEX FASPRO compared with standard regimens, as described in a market news report.

TALVEY is Johnson & Johnson’s therapy for multiple myeloma, and DARZALEX FASPRO is a subcutaneous formulation of daratumumab, also used in myeloma treatment. In the MonumenTAL-3 trial, Johnson & Johnson’s approach pairs TALVEY with DARZALEX FASPRO, aiming to enhance response rates and disease control by using therapies with complementary roles in myeloma treatment plans.

According to the Yahoo Finance write-up, the reported results represent a positive Phase 3 readout for the TALVEY combination. The report also characterizes MonumenTAL-3 as the first Phase 3 study for the TALVEY combination, positioning the data as a potential step toward broader clinical use if further details and regulatory review support the findings.

The article did not provide specific efficacy or safety metrics such as median progression-free survival, overall response rates, or adverse event rates in the portion available for this review. It also did not specify which “standard regimens” were used for comparison, nor whether Johnson & Johnson expects to file for regulatory approval immediately based on these results.

From a business perspective, a Phase 3 success in an oncology indication can matter because it expands the evidence base needed for formulary placement, treatment guideline adoption, and potential payer coverage decisions. For Johnson & Johnson, adding a stronger clinical rationale for TALVEY as part of combination therapy could influence how clinicians sequence treatment for myeloma patients, particularly those who have already received prior lines of therapy.

Multiple myeloma remains a crowded competitive landscape with a steady stream of new and improved treatments across different mechanisms. In that context, Johnson & Johnson’s reported Phase 3 momentum on a combination approach could help position TALVEY more firmly beyond earlier-line or limited settings, depending on how regulators and guideline committees interpret the data.

Still, important details remain unreported in the available market-news coverage. Without the trial’s statistical endpoints, subgroup results, duration of follow-up, and a full safety profile, investors and clinicians cannot yet assess how durable the benefits may be or how the risk-benefit balance compares with existing standard-of-care options.

Looking ahead, the next key items to watch are the full presentation or publication of MonumenTAL-3 results, including primary and secondary endpoint outcomes and safety, as well as any stated plans for regulatory filings in relevant jurisdictions. Those steps will determine whether the Phase 3 “win” translates into approvals and real-world uptake for the TALVEY plus DARZALEX FASPRO regimen.